Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee granted equity awards to three new employees on November 1, 2024. The grants include 79,500 non-qualified stock options at $3.32 per share and 21,000 restricted stock units under the 2022 Employment Inducement Incentive Award Plan. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over three years. The restricted stock units will vest in 25% increments annually over four years, subject to continued employment.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) ha annunciato che il suo Comitato di Compensazione ha concesso premi azionari a tre nuovi dipendenti il 1° novembre 2024. I premi includono 79.500 opzioni su azioni non qualificate a 3,32 dollari per azione e 21.000 unità azionarie vincolate secondo il Piano di Incentivazione per l'Occupazione 2022. Le opzioni su azioni si matureranno in quattro anni, con il 25% che matura dopo un anno e il resto mensilmente nei tre anni successivi. Le unità azionarie vincolate si matureranno in incrementi del 25% annualmente per quattro anni, a condizione di un'occupazione continuativa.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) anunció que su Comité de Compensación otorgó premios de acciones a tres nuevos empleados el 1 de noviembre de 2024. Los premios incluyen 79,500 opciones de acciones no calificadas a 3.32 dólares por acción y 21,000 unidades de acciones restringidas bajo el Plan de Incentivos por Empleo 2022. Las opciones de acciones se asignarán en un período de cuatro años, con el 25% asignándose después de un año y el resto mensualmente durante los tres años siguientes. Las unidades de acciones restringidas se asignarán en incrementos del 25% anualmente durante cuatro años, sujeto a la continuación del empleo.
젠탈리스 제약 (Nasdaq: ZNTL)는 2024년 11월 1일에 보상위원회가 세 명의 신규 직원에게 주식 보상을 승인했다고 발표했습니다. 이 보상에는 79,500개의 비자격 주식 옵션이 주당 3.32달러로 포함되며, 21,000개의 제한 주식 유닛도 2022 고용 유도 인센티브 상금 계획에 따라 수여됩니다. 주식 옵션은 4년에 걸쳐 분할되어 부여되며, 1년 후 25%가 부여되고 나머지는 3년에 걸쳐 매달 부여됩니다. 제한 주식 유닛은 4년에 걸쳐 매년 25%씩 부여되며, 계속 고용되는 조건이 있습니다.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) a annoncé que son Comité de Rémunération avait accordé des récompenses en actions à trois nouveaux employés le 1er novembre 2024. Les récompenses comprennent 79 500 options d'actions non qualifiées à 3,32 dollars par action et 21 000 unités d'actions restreintes dans le cadre du Plan d'Incitation à l'Emploi 2022. Les options d'actions acquerront des droits sur une période de quatre ans, avec 25 % acquérant des droits après un an et le reste mensuellement sur trois ans. Les unités d'actions restreintes acquerront des droits par tranches de 25 % chaque année pendant quatre ans, sous réserve d'un emploi continu.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) hat bekannt gegeben, dass sein Vergütungsausschuss am 1. November 2024 Aktienvergaben an drei neue Mitarbeiter genehmigt hat. Die Vergaben umfassen 79.500 nicht qualifizierte Aktienoptionen zu einem Preis von 3,32 Dollar pro Aktie und 21.000 eingeschränkte Aktieneinheiten im Rahmen des 2022 Employment Inducement Incentive Award Plans. Die Aktienoptionen werden über vier Jahre fällig, wobei 25% nach einem Jahr und der Rest monatlich über drei Jahre fällig wird. Die eingeschränkten Aktieneinheiten werden in jährlichen 25%-Schritten über vier Jahre fällig, vorausgesetzt, das Arbeitsverhältnis bleibt bestehen.
- Successful attraction of new talent with equity-based compensation
- Potential shareholder dilution from new equity grants
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 79,500 shares of the Company’s common stock and 21,000 restricted stock units to three newly hired employees. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options and restricted stock units is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors and hematologic malignancies. Azenosertib is being evaluated as a monotherapy and in combination across multiple clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. As part of its azenosertib clinical development program, the Company is exploring enrichment strategies targeting tumors of high genomic instability, such as Cyclin E1 positive tumors, homologous recombination deficient tumors and tumors with oncogenic driver mutations. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contacts:
Elizabeth Hickin
Vice President, Investor Relations
ehickin@zentalis.com
FAQ
What is the exercise price of the stock options granted by Zentalis (ZNTL) on November 1, 2024?
How many shares were included in Zentalis (ZNTL) November 2024 inducement grants?
What is the vesting schedule for Zentalis (ZNTL) November 2024 stock options?
